A randomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
Indications Gastric cancer
Focus Therapeutic Use
Acronyms HERBIS-4A

02 Jul 2022 Results integrated analysis of three phase II randomized trials (HERBIS-2, HERBIS-4A, and XParTS II) with the use of individual participant data (IPD) from each trial, presented at the 24th World Congress on Gastrointestinal Cancer.
25 Jan 2020 Results of pooled analysis from HERBIS-2 and HERBIS-4A studies presented at the 2020 Gastrointestinal Cancers Symposium.
20 Feb 2019 Status changed to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com